NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 16 Sep 2019 (#30)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit **www.grants.nih.gov** or **www.sun.ac.za/RDSfunding** (current & archive).*

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **NOT-HD-19-024 - Notice of Intent to Publish a Funding Opportunity Announcement for the Pediatric HIV AIDS Cohort Study Program Project Grant Applications (P01 Clinical Trial Not Allowed)** The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intends to publish a FOA. Pediatric HIV/AIDS Cohort Study (PHACS), which addresses critical scientific questions on the clinical course of perinatally acquired HIV infection in adolescents and young adults and the oral and systemic health consequences of in utero and infant exposure to antiretroviral therapy in representative cohorts of children in the United States. The findings from this domestically based initiative have great relevance internationally since millions of HIV-infected children in resource-constrained settings receive treatment and survive into adolescence and adulthood and many pregnant women with HIV have access to and use combination antiretroviral therapy to prevent infant HIV infection and preserve their own health. Collaborative, synergistic Program Projects (P01) Grants comprised of at least three component projects and associated cores are planned. The proposed research should integrate basic, translational, and/or clinical approaches. The component projects must share a common central theme and research focus. At least two groups will be studied in the PHACS: HIV exposed uninfected (HEU) and youth with perinatal HIV(PHIV). New HEU enrollments will continue to capture the evolving type and timing of antiretrovirals during pregnancy. Timing of antiretroviral initiation continues to evolve, and more women are on treatment at the time of conception or earlier in pregnancy. PHACS will support ongoing evaluations of in utero and postnatal exposures to new antiretroviral drugs in the HEU cohort and identify specific adverse events and potential etiologic factors. The transition to adulthood of youth with PHIV treated with ART provides an important opportunity for PHACS to examine a host of health outcomes, including reproduction, oral, cognitive, neurodevelopmental, mental health, substance use, behavioral, emotional, social, academic and vocational outcomes. Since this cohort includes youth who received very early treatment and have had nearly lifelong HIV suppression, there is also a unique opportunity to glean insights that may inform HIV cure research. Collaborations will continue to be encouraged with other cohorts in both resource-rich and resource-constrained settings. **First Estimated Application Due Date: December 06, 2019**
- **Don't Forget to Link Your ORCID iD to Your eRA Commons Profile**: Starting October 1, 2019, ORCID identifiers will be required for individuals supported by institutional research training, career development, and other research education awards.
- **New Centralized Notification for Unfunded Applications Applicant** organizations will begin receiving centralized email notifications listing applications that NIH does not intend to fund from the Advisory Council held approximately 14 months prior.
- **Reference Letters vs. Letters of Support: What's the Difference?** Reference letters and letters of support provide key information for reviewers and NIH staff. Check out this table for an overview of when each letter is used, who writes them, and what should be included

1. Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** PAR-19-357 **Type:** R01
PAR-19-364 R21

Application Due Date: January 8, 2020; January 8, 2021; January 10, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.
R21- The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

2. Planning Grant for Global Infectious Disease Research Training Program (Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** PAR-19-362 **Type:** D71

Application Due Date: November 12, 2019, October 28, 2020, October 28, 2021 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications for a planning grant from institutions in low- and middle-income countries (LMICs) to 1) Design a Global Infectious Disease (GID) Research Training Program in collaboration with U.S. collaborators and 2) Strengthen LMIC faculty and prepare advanced courses and training resources for the program envisioned at the LMIC institution. The application should propose a collaborative process to create a new training program that will strengthen the capacity of the LMIC institution to conduct infectious disease research. Applications should include activities to strengthen LMIC faculty leadership and skills as well as prepare advanced scientific didactic and methodology courses and research training resources development relevant to the program to be planned. A detailed vision for a research training program that focuses on a major endemic or life-threatening emerging infectious disease, neglected tropical disease, infections that frequently occur as a co-infection in HIV infected individuals, or infections associated with non-communicable disease conditions of public health importance in LMICs should be proposed. This Funding Opportunity Announcement (FOA) does not allow research training in clinical trials.

Budget: Application budgets are limited to $100,000 (total direct costs) per year. The maximum project period is 2 years.

3. Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** RFA-HD-20-020 **Type:** R21

Application Due Date: November 1, 2019 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to continue the encouragement of the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology, pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations.

Budget: NICHD intends to commit $1,000,000 in FY 2020 to fund up to 5 new awards and is contingent upon NIH appropriations. Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct cost in any year.

4. Mechanistic Basis of TDP-43-dependent Pathobiology in Common Dementias (Clinical Trial not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** RFA-NS-20-005 **Type:** R01

Application Due Date: November 15, 2019 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research on the systems, cellular and/or molecular mechanisms and consequences of TDP-43 proteinopathy in common dementias using whole animal models, animal/human cellular model systems, as well as postmortem tissue and other biospecimens. Research on TDP-43 proteinopathy in common dementias, including the clinical syndrome of Alzheimer's disease (AD), multiple etiology dementias (MED) and related dementia syndromes is the focus of this FOA. In addition, comparative studies of TDP-43 proteinopathy in common and rare neurodegenerative diseases, as well as during normal aging and in pre-symptomatic disease stages are within scope.

Budget: NINDS intends to commit $6,750,000 in FY 2020 to fund 8-10 awards. Application budgets are limited to up to $500,000 direct costs per year, and should reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. Peripheral Pathology in the Lewy Body Dementias (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** RFA-NS-20-014 **Type: R01**
Application Due Date: December 3, 2019 by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this initiative is to identify potential diagnostic markers for the Lewy Body Dementias using non-blood or non-CSF peripheral specimens and tissues (e.g., skin, salivary gland, gastrointestinal tract, etc.). Blood and CSF have traditionally and extensively been examined for neurodegenerative disease biomarkers; however, research suggests that abnormal alpha-synuclein accumulation occurs in other peripheral tissues and specimens early in the disease course and may provide opportunities for early diagnosis and future treatment development.
Budget: NINDS intends to commit $3,750,000 in FY 2020 to fund 5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: ***Christa***
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: ***Lizél***
e: lizelk@sun.ac.za | t: +27 21 808 2105